ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2124

Reliability and Validation of the Physician’s Global Assessment of Lung Disease (PGALD) in Systemic Juvenile Idiopathic Arthritis -Associated Lung Disease (SJIA-LD)

Eileen Rife1, Guihua Zhai2, Mekibib Altaye3, Jennifer Andringa4, Hermine Brunner5, Scott Canna6, Lauren Henderson7, Yukiko Kimura8, Scott Lieberman9, Mona Riskalla10, Tiphanie Vogel11, Holly Wobma12 and Grant Schulert5, 1University of Alabama at Birmingham, birmingham, AL, 2UAB, Birmingham, 3Cincinnati Children's Hospital, Cincinnati, 4Cincinnati Children's Hospital Medical Center, Cincinnati, 5Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 6Children's Hospital of Philadelphia, Philadelphia, PA, 7Boston Children's Hospital, Watertown, MA, 8Hackensack Meridian School of Medicine, New York, NY, 9University of Iowa, Iowa City, IA, 10University of Minnesota Masonic Children's Hospital, Minneapolis, MN, 11Baylor College of Medicine, Houston, TX, 12Boston Children's Hospital, Boston, MA

Meeting: ACR Convergence 2025

Keywords: Disease Activity, Pediatric rheumatology, Still's disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2124–2158) Pediatric Rheumatology – Clinical Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: The physician global assessment of lung disease (PGALD) is a recently proposed disease activity measure for patients with systemic juvenile idiopathic arthritis-associated lung disease (SJIA-LD) – a significant cause of morbidity and mortality in SJIA. This study evaluates the reliability and construct validity of the PGALD.

Methods: 20 SJIA-LD clinical vignettes were created, informed by historical patient encounters as templates. Vignettes included brief patient medical histories, physical examination findings, a list of prescribed medications, laboratory results, diagnostic imaging, pulmonary function test results, and biopsy results – when available. Fifty-seven pediatric rheumatologists and pulmonologists with experience caring for children with SJIA-LD were invited to rate vignettes utilizing the PGALD, a 10-point Likert scale (0 = inactive SJIA-LD; 10 = highly active SJIA-LD). Raters who completed the initial round of 20 vignettes were asked three days later to rate a subset of 8 repeat vignettes. Inter- and intra-rater reliability were assessed using intraclass correlation coefficients (ICC). Based on the 95% confidence interval of ICC estimates, values less than 0.5 indicated poor reliability, between 0.5-0.75 moderate-, between 0.76-0.9 good-, and >0.9 excellent reliability. SJIA-LD features influencing PGALD ratings were assessed in univariate analysis.

Results: The ICC for all raters was 0.678 (0.543, 0.819), indicating moderate to good inter-rater reliability. The intra-rater ICC was 0.863 (0.823, 0.893) indicating good intra-rater reliability. Factors associated with higher mean PGALD scores included the presence of crackles on auscultation (5.7 vs. 2.9; p=0.001), hypoxemia on pulse oximeter (5.6 vs. 3.2; p=0.01), current oxygen requirement (6.3 vs. 3.5; p=0.04), suggestive diagnostic imaging features (p≤0.01), and three or more prescribed medications for SJIA-LD (p≤0.01). Pulmonary function measures demonstrated significant negative correlations with mean PGALD scores, including forced vital capacity (r=−0.71; p=0.01), total lung capacity (r=−0.92; p=0.01), and diffusion capacity (r=−0.97; p=0.0002). Only the CRP was weak-to-moderately correlated with PGALD scores (r=0.39; p=0.09), while other laboratory values including ferritin, IL-18, CXCL9, and sIL2R were not significantly correlated.

Conclusion: The PGALD is a novel measure of SJIA-associated LD activity. Its initial validation suggests acceptable construct validity and reliability. Additional studies are needed to assess its responsiveness to change over time.

Supporting image 1

Supporting image 2Sp02 – Peripheral saturation of oxygen; MAS – macrophage activation syndrome; IL-18 – Interleukin 18; CRP – C-reactive protein; CXCL9 chemokine c-x-c-motif; FVC – forced vital capacity; TLC – Total Lung capacity; DLCO – lung diffusion capacity.

Unpaired t test performed for Clinical Variables, Laboratory Elevation and Diagnostic Imaging Features; Pearson Correlation Coefficient performed for Laboratory Values and Pulmonary function Test Values; ANOVA performed for Number of Medications Prescribed.

Supporting image 3Association between clinical features and mean PGALD scores. A: Mean PGALD scores in patients with vs. without supplemental oxygen. B: Mean PGALD scores in patients with vs. without hypoxia. C: Mean PGALD scores in patients with vs. without crackles on exam. D: Mean PGALD scores by number of medications (1-5) used to treat SJIA-LD. *p= < 0.05, **p= < 0.01


Disclosures: E. Rife: None; G. Zhai: None; M. Altaye: None; J. Andringa: None; H. Brunner: AbbVie, 2, AstraZeneca-Medimmune, 2, Biogen, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, Eli Lilly, 2, EMD Serono, 2, F. Hoffmann-La Roche, 2, Genentech, 5, GlaxoSmithKline, 2, Merck, 2, Novartis, 2, Pfizer, 2, 5, Sanofi, 2, UCB, 2; S. Canna: AB2Bio, 2, Bristol-Myers Squibb(BMS), 2, Novartis, 2, Simcha Therapeutics, 12, In-kind provision of a reagent, Sobi, 6; L. Henderson: Bristol-Myers Squibb(BMS), 5, Pfizer, 2, Sobi, 2; Y. Kimura: None; S. Lieberman: None; M. Riskalla: SOBI, 2; T. Vogel: AstraZeneca, 5, moderna, 2, Pfizer, 2, SOBI, 1, 2, takeda, 6; H. Wobma: None; G. Schulert: IpiNovoyx, 5, Novartis, 2, SOBI, 2.

To cite this abstract in AMA style:

Rife E, Zhai G, Altaye M, Andringa J, Brunner H, Canna S, Henderson L, Kimura Y, Lieberman S, Riskalla M, Vogel T, Wobma H, Schulert G. Reliability and Validation of the Physician’s Global Assessment of Lung Disease (PGALD) in Systemic Juvenile Idiopathic Arthritis -Associated Lung Disease (SJIA-LD) [abstract]. Arthritis Rheumatol. 2025; 76 (suppl 9). https://acrabstracts.org/abstract/reliability-and-validation-of-the-physicians-global-assessment-of-lung-disease-pgald-in-systemic-juvenile-idiopathic-arthritis-associated-lung-disease-sjia-ld/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reliability-and-validation-of-the-physicians-global-assessment-of-lung-disease-pgald-in-systemic-juvenile-idiopathic-arthritis-associated-lung-disease-sjia-ld/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology